Jasper Therapeutics (JSPR) Non Operating Interest Expenses (2023 - 2024)
Jasper Therapeutics (JSPR) posted Non Operating Interest Expenses of $40000.0 for Q2 2024, up 81.82% on a QoQ basis from $22000.0 in Q1 2024, and down 63.3% year-over-year from $109000.0 in Q3 2023.
Powered by 
Analysis
Jasper Therapeutics (JSPR) Non Operating Interest Expenses (2023 - 2024) Analysis & Trends
Jasper Therapeutics has reported Non Operating Interest Expenses for 2 years, with the latest figure at $40000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Jasper Therapeutics | 20.11 Mn | 20.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 40,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Jun 30, 2023 | 109,000.00 |
| Mar 31, 2023 | 70,000.00 |